EUVIMEDEUVIMED entdecken
Crossref

CD34+ cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma

Ahmet Sarıcı, Mehmet Ali Erkurt, İrfan Kuku, Emin Kaya, İlhami Berber, Soykan Biçim, Emine Hidayet, Ahmet Kaya, Aşkı Vural, Onur Selçuk Yiğit, Mehmet Fatih Uzanulu, Musa Ak

Journal of Current Hematology & Oncology Research · 18.05.2026 · 4 (2) · 47-52

DOI: 10.51271/jchor-0081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 18.05.2026. Verfasst von Ahmet Sarıcı und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters—particularly the infused CD34+ cell dose—play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34+ cell dose.

Methods

Demographic characteristics, primary diagnosis, infused CD34+ cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34+ cell dose: 2–5 × 106/kg and >5 × 106/kg. Engraftment times and survival outcomes were compared between groups.

Results

A total of 165 patients were included (2–5 × 106/kg, n = 67; >5 × 106/kg, n = 98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2–5 × 106/kg group than in the >5 × 106/kg group (p < 0.001 for both). In the overall cohort, CD34+ cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups.

Conclusion

Adequate CD34+ cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.

Zitieren

APA

Sarıcı, A., Erkurt, M. A., Kuku, İ., Kaya, E., Berber, İ., Biçim, S., Hidayet, E., Kaya, A., Vural, A., Yiğit, O. S., Uzanulu, M. F., & Ak, M. (2026). CD34+ cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma. Journal of Current Hematology & Oncology Research, 4(2), 47-52. https://doi.org/10.51271/jchor-0081

Vancouver

Sarıcı A, Erkurt MA, Kuku İ, Kaya E, Berber İ, Biçim S, et al. CD34+ cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma. Journal of Current Hematology & Oncology Research. 2026;4(2):47-52. doi:10.51271/jchor-0081

BibTeX
@article{Sarc2026,
  author = {Sarıcı, Ahmet and Erkurt, Mehmet Ali and Kuku, İrfan and Kaya, Emin and Berber, İlhami and Biçim, Soykan and Hidayet, Emine and Kaya, Ahmet and Vural, Aşkı and Yiğit, Onur Selçuk and Uzanulu, Mehmet Fatih and Ak, Musa},
  title = {CD34+ cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma},
  journal = {Journal of Current Hematology & Oncology Research},
  year = {2026},
  volume = {4},
  number = {2},
  pages = {47--52},
  doi = {10.51271/jchor-0081}
}
Kostenlos starten →